Competitor drugs entering the market are opening opportunities to make important savings on an increasing number of biological anticancer agents. But, as Rachel Brazil reports, many countries, including those with the most stretched health budgets, [more]
Despite growing precision in understanding the biology of breast cancer, progress in extending survival of people with metastatic disease remains frustratingly slow. Median survival is only about three years, having edged up only slightly in [more]
An ESO task force met to discuss the potential for “biosimilar” medical products in oncology, analyzing facts and debunking some myths. Some of the most used biologic drugs in oncology are going off patent in [more]
As patents on the first generation of monoclonal antibodies begin to expire, the cancer community will need to get to grips with the unique issues involved in ensuring the safety and efficacy of copies of [more]